Guam
Hepatitis B
Download HBV dataPrevalence of chronic HBV (HBsAg+)
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 5.03 (4.31 - 5.86) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 5.62 (4.81 - 6.47) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.7 (4.78 - 6.69) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.84 (5 - 6.79) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.97 (5.06 - 6.97) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.95 (5.05 - 6.91) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.9 (5.03 - 6.76) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.84 (4.97 - 6.69) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.8 (4.91 - 6.64) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.77 (4.88 - 6.66) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.8 (4.94 - 6.65) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.85 (5 - 6.69) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.92 (5.07 - 6.80) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.97 (5.08 - 6.86) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.99 (5.08 - 6.96) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.96 (5.05 - 6.89) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.9 (4.97 - 6.85) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.82 (4.84 - 6.82) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.76 (4.74 - 6.77) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.74 (4.67 - 6.78) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.79 (4.76 - 6.82) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.92 (4.94 - 6.99) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.07 (5.14 - 7.24) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.2 (5.27 - 7.44) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.26 (5.33 - 7.56) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.25 (5.33 - 7.47) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.24 (5.29 - 7.51) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.21 (5.22 - 7.46) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.16 (5.12 - 7.43) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.09 (4.94 - 7.36) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.5 (4.72 - 6.36) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
Children under-5 years
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 0 | 2015 | Survey/reported | WHO WPRO, Woodring J et al, 2017 |
| 2.08 (1.41 - 2.84) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 2.6 (1.75 - 3.57) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.63 (1.80 - 3.65) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.65 (1.80 - 3.72) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.74 (1.88 - 3.73) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.83 (1.91 - 3.82) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.81 (1.92 - 3.77) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.75 (1.89 - 3.65) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.69 (1.84 - 3.56) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.64 (1.80 - 3.49) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.62 (1.79 - 3.47) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.65 (1.80 - 3.51) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.7 (1.82 - 3.59) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.77 (1.84 - 3.67) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.83 (1.85 - 3.78) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.87 (1.85 - 3.84) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.87 (1.87 - 3.85) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.86 (1.87 - 3.84) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.84 (1.84 - 3.81) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.83 (1.83 - 3.80) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.82 (1.80 - 3.84) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.85 (1.85 - 3.85) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.89 (1.92 - 3.96) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.94 (1.97 - 4.11) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.99 (2.03 - 4.26) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.01 (2.06 - 4.32) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.02 (2.06 - 4.29) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.02 (2.06 - 4.26) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.02 (2.06 - 4.20) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.01 (2.04 - 4.15) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3 (2.01 - 4.11) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
Number of people living with chronic HBV
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 8,591 (7,353 - 9,992) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 8,946 (7,694 - 10,362) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9,108 (7,799 - 10,508) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9,186 (7,682 - 10,803) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9,369 (8,015 - 10,918) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9,545 (8,103 - 11,086) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9,460 (8,046 - 10,945) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9,336 (7,960 - 10,710) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9,200 (7,830 - 10,531) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9,081 (7,688 - 10,422) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9,007 (7,583 - 10,401) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9,005 (7,672 - 10,332) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9,054 (7,731 - 10,361) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9,120 (7,813 - 10,470) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9,168 (7,809 - 10,584) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9,165 (7,778 - 10,667) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9,087 (7,713 - 10,512) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8,959 (7,553 - 10,413) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8,812 (7,349 - 10,333) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8,679 (7,150 - 10,225) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8,589 (6,996 - 10,160) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8,604 (7,075 - 10,124) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8,711 (7,239 - 10,305) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8,845 (7,458 - 10,526) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8,923 (7,589 - 10,674) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8,868 (7,543 - 10,721) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8,719 (7,425 - 10,439) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8,544 (7,235 - 10,253) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8,342 (7,027 - 10,035) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8,110 (6,748 - 9,781) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7,847 (6,382 - 9,498) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
HBV-related death rate
National
Download| Value (per 100,000) | Year | Type | Source |
|---|---|---|---|
| 11.9 (9.61 - 14.80) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 7.12 (5.89 - 8.58) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.22 (5.94 - 8.65) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.3 (6 - 8.70) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.39 (6.02 - 8.77) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.29 (6 - 8.72) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.48 (6.14 - 8.90) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.26 (6.01 - 8.69) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.4 (6.17 - 8.77) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.73 (6.45 - 9.17) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.01 (6.72 - 9.51) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.25 (6.87 - 9.77) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.27 (6.92 - 9.77) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.45 (7.04 - 9.98) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.6 (7.18 - 10.13) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.82 (7.37 - 10.37) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.66 (7.25 - 10.18) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.14 (7.61 - 10.69) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.4 (7.90 - 11.07) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.66 (8.17 - 11.37) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 10.11 (8.54 - 11.88) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.94 (8.43 - 11.63) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 10.21 (8.59 - 12.02) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 10.53 (8.89 - 12.45) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 10.89 (9.18 - 12.86) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 11.57 (9.63 - 13.97) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 11.19 (9.38 - 13.27) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 11.43 (9.62 - 13.71) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 11.63 (9.55 - 14.12) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 11.71 (9.57 - 14.44) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 11.89 (9.61 - 14.76) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
HBV-related deaths
National
Download
Showing out of
Show more
Percent of liver cancer deaths attributable to HBV
National
Download
Showing out of
Show more
Number of needles/syringes per PWID per year
People who inject drugs (PWID)
Download| Value | Year | Type | Source |
|---|---|---|---|
| 0 (0 - 0) | 2016 | Survey/reported | Harm Reduction International, 2016 |
Percent of PWID accessing OST
People who inject drugs (PWID)
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 0 | 2016 | Survey/reported | Harm Reduction International, 2016 |
Eligible for HBV generic medicines
Eligible for HCV generic medicines
Hepatitis C
Download HCV dataPrevalence of chronic HCV (RNA+/cAg)
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 0.45 (0.37 - 0.55) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.45 (0.37 - 0.55) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.45 (0.37 - 0.55) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.45 (0.37 - 0.54) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.45 (0.37 - 0.54) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.45 (0.37 - 0.55) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.45 (0.37 - 0.54) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.45 (0.37 - 0.54) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.45 (0.37 - 0.55) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.45 (0.37 - 0.55) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.45 (0.36 - 0.55) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.45 (0.37 - 0.54) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.45 (0.37 - 0.54) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.45 (0.37 - 0.54) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.45 (0.37 - 0.54) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.45 (0.37 - 0.54) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.45 (0.37 - 0.55) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.46 (0.37 - 0.55) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.46 (0.37 - 0.56) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.46 (0.37 - 0.56) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.46 (0.37 - 0.56) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.47 (0.38 - 0.56) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.47 (0.38 - 0.57) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.47 (0.38 - 0.57) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.48 (0.39 - 0.58) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.48 (0.38 - 0.58) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.47 (0.38 - 0.58) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.47 (0.38 - 0.58) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.47 (0.38 - 0.58) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.47 (0.37 - 0.57) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.43 (0.34 - 0.52) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
Showing out of
Show more
Women of childbearing age (15–49 years)
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 1.44 (1.09 - 4.97) | 2019 | Modelled | Dugan et al., 2021 |
Number of people living with chronic HCV (RNA+/cAg)
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 601 (481 - 740) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 619 (497 - 757) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 635 (512 - 770) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 650 (523 - 791) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 663 (537 - 808) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 674 (545 - 820) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 681 (554 - 826) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 685 (558 - 829) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 686 (559 - 832) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 687 (558 - 833) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 689 (556 - 838) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 691 (563 - 838) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 690 (564 - 835) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 689 (562 - 832) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 688 (559 - 829) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 688 (560 - 830) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 690 (564 - 833) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 693 (566 - 837) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 696 (566 - 842) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 699 (571 - 849) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 701 (570 - 856) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 704 (576 - 858) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 707 (578 - 856) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 710 (579 - 860) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 712 (584 - 864) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 716 (583 - 868) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 720 (592 - 871) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 725 (594 - 882) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 731 (601 - 885) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 727 (583 - 883) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 738 (604 - 892) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
Women of childbearing age (15–49 years)
Download| Value | Year | Type | Source |
|---|---|---|---|
| 580 (440 - 2,000) | 2019 | Modelled | Dugan et al., 2021 |
HCV-related death rate
National
Download| Value (Deaths per 100,000) | Year | Type | Source |
|---|---|---|---|
| 5.03 (3.75 - 6.59) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 3.66 (2.80 - 4.74) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.72 (2.86 - 4.79) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.76 (2.86 - 4.84) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.8 (2.89 - 4.92) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.72 (2.85 - 4.83) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.83 (2.90 - 5.01) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.7 (2.85 - 4.79) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.8 (2.90 - 4.86) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.7 (2.83 - 4.74) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.87 (2.95 - 4.96) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.91 (2.99 - 5.02) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.91 (3.01 - 4.98) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.87 (2.97 - 4.94) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.94 (3.05 - 5.01) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.9 (3.03 - 4.95) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.93 (3.01 - 4.98) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.05 (3.11 - 5.14) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.14 (3.17 - 5.25) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.24 (3.22 - 5.40) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.34 (3.30 - 5.55) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.38 (3.35 - 5.61) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.39 (3.37 - 5.61) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.5 (3.46 - 5.71) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.61 (3.56 - 5.89) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.7 (3.61 - 6.02) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.78 (3.64 - 6.17) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.82 (3.64 - 6.25) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.88 (3.71 - 6.29) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.92 (3.71 - 6.47) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.03 (3.75 - 6.59) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
HCV-related deaths
National
Download
Showing out of
Show more
Percent of liver cancer deaths attributable to HCV
National
Download
Showing out of
Show more
Number of needles/syringes per PWID per year
People who inject drugs (PWID)
Download| Value | Year | Type | Source |
|---|---|---|---|
| 0 (0 - 0) | 2016 | Survey/reported | Harm Reduction International, 2016 |
Percent of PWID accessing OST
People who inject drugs (PWID)
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 0 | 2016 | Survey/reported | Harm Reduction International, 2016 |
Eligible for HBV generic medicines
Eligible for HCV generic medicines
Overview
Prevalence (national)
Modelled
Survey/surveillance
No data available
No data available
Hepatitis related deaths (national)
Modelled
HBV
20
2019
(16 - 25)
IHME, GBD 2019 (accessed 2022)
Survey/surveillance
No data available
HBV chart
Modelled
HCV
9
2019
(6 - 11)
IHME, GBD 2019 (accessed 2022)
Survey/surveillance
No data available
HCV chart
Prevalence PWID
No data available
Birth dose vaccination coverage (national)
Survey/surveillance
No data available
Eligible for HBV generic medicines
Eligible for HCV generic medicines